Derek Archila
Stock Analyst at Wells Fargo
(3.85)
# 682
Out of 4,981 analysts
183
Total ratings
49.58%
Success rate
9.76%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Overweight | $44 → $38 | $24.44 | +55.51% | 4 | Aug 20, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $123 | $53.62 | +129.39% | 1 | Aug 20, 2025 | |
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.88 | +242.11% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $1.84 | +8.70% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $195.58 | +50.83% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.49 | +235.57% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $18.87 | +37.82% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $7.74 | +106.72% | 7 | Aug 7, 2025 | |
| INCY Incyte | Upgrades: Overweight | $67 → $89 | $83.10 | +7.10% | 9 | Aug 6, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $741 → $756 | $756.38 | -0.05% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.37 | +289.02% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $96.22 | +34.07% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $47.00 | +12.77% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $25 | $6.03 | +314.59% | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $24.85 | +16.70% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $14.28 | +26.05% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $9.05 | +176.24% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.81 | +107.90% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.88 | +697.87% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $39.15 | -8.05% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $23.40 | +117.95% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $15.73 | -11.00% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.93 | +129.30% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.16 | +178.47% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $2.66 | +351.13% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.92 | +512.24% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.30 | +378.26% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.42 | +313.22% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.84 | +604.23% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.61 | +220.86% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.30 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $32.05 | +502.18% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $73.05 | -43.87% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.01 | +965.96% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.87 | +507.90% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.51 | +543.02% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.26 | +3,868.25% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $18.79 | +171.42% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $22.27 | +295.15% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $27.12 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $19.93 | - | 2 | Aug 3, 2017 |
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $24.44
Upside: +55.51%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $53.62
Upside: +129.39%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.88
Upside: +242.11%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.84
Upside: +8.70%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $195.58
Upside: +50.83%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.49
Upside: +235.57%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $18.87
Upside: +37.82%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $7.74
Upside: +106.72%
Incyte
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $83.10
Upside: +7.10%
argenx SE
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $756.38
Upside: -0.05%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.37
Upside: +289.02%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $96.22
Upside: +34.07%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $47.00
Upside: +12.77%
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $6.03
Upside: +314.59%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $24.85
Upside: +16.70%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $14.28
Upside: +26.05%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $9.05
Upside: +176.24%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.81
Upside: +107.90%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.88
Upside: +697.87%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $39.15
Upside: -8.05%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $23.40
Upside: +117.95%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $15.73
Upside: -11.00%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.93
Upside: +129.30%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.16
Upside: +178.47%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $2.66
Upside: +351.13%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.92
Upside: +512.24%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.30
Upside: +378.26%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.42
Upside: +313.22%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.84
Upside: +604.23%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.61
Upside: +220.86%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.30
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $32.05
Upside: +502.18%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $73.05
Upside: -43.87%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.01
Upside: +965.96%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.87
Upside: +507.90%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.51
Upside: +543.02%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.26
Upside: +3,868.25%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $18.79
Upside: +171.42%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $22.27
Upside: +295.15%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $27.12
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $19.93
Upside: -